Preclinical evaluation of lentinan in animal models.
Lentinan exerts prominent antitumor effects in allogeneic, syngeneic and autochthonous hosts and prevents chemical and viral carcinogenesis, and increases host-resistance to bacterial, viral and parasitic infections. Lentinan augments helper T cell mediated cytotoxic T cell activity, NK cell activity and humoral immune responses, and activates nonspecific cytotoxicity of macrophages in vivo. Lentinan is a representative of a unique class of T cell adjuvants, and has no toxicity. Therefore, lentinan is suitable for clinical application for cancer patients from the results in its preclinical animal model experiments.
D000276:Adjuvants, Immunologic; D000818:Animals; D004353:Drug Evaluation, Preclinical; D007912:Lentinan / Q000009:adverse effects / Q000627:therapeutic use*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology; D011134:Polysaccharides / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D011134:Polysaccharides; D007912:Lentinan